Vincent Muczynski

Join researcher Vincent Muczynski, who presents a groundbreaking AAV gene therapy strategy for hemophilia A using a novel bispecific antibody. He details impressive preclinical results showing promise in correcting bleeding in mice. Clinician-scientist Mark Geyer unveils his phase 1 study on CD371-targeted CAR T cells infused with interleukin-18, which shows potential in tackling relapsed/refractory acute myeloid leukemia. Translational scientist Susan DeWolf shares insights from their analyses, revealing how interleukin-18 fosters immune remodeling and enhances treatment effectiveness.